Aurora Spine Q4 revenue rises 6.8%

Aurora Spine

30/04/2026 12:31

Corrects period to Q4, from Q1, in Key Details table

Overview

Spinal implant maker's Q4 revenue rose 6.8% yr/yr

Q4 EBITDAC improved to $301,112 from a loss in prior year period

Revenue growth driven by higher Zip implant, SI fusion device sales and new biologics launch

Outlook

Company expects sales of DEXA product line to build throughout 2026

Result Drivers

PRODUCT MIX - Higher gross margin attributed to increased sales of higher-margin implants, lower distributor commissions, and reduced royalty expenses

ZIP AND SI FUSION SALES - Revenue growth driven by increased sales in Zip implants and SI fusion devices, as well as the release of the facet fusion device

BIOLOGICS LAUNCH - Launch of Aurora Biologics contributed to a $0.2 mln increase in biologic sales for 2025, with most growth in the second half

Company press release: ID:nGNX99X42X

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$5.02 mln


Analyst Coverage

The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)